An open-label study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the AKT [protein kinase B] inhibitor GSK690693 given on various schedules in subjects with solid tumors or lymphoma.

Trial Profile

An open-label study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the AKT [protein kinase B] inhibitor GSK690693 given on various schedules in subjects with solid tumors or lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs GSK 690693 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Mar 2007 to Apr 2007 as reported by Clinicaltrials.gov.
    • 12 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top